PCVX
Price
$56.69
Change
-$1.58 (-2.71%)
Updated
Sep 29 closing price
Capitalization
8.67B
40 days until earnings call
Intraday BUY SELL Signals
PTGX
Price
$140.97
Change
-$1.47 (-1.03%)
Updated
Sep 29 closing price
Capitalization
9.22B
36 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PCVX vs PTGX

PCVX vs PTGX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PCVX vs. PTGX commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCVX is a StrongBuy and PTGX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
PCVX vs PTGX: Fundamental Ratings
PCVX
PTGX
OUTLOOK RATING
1..100
1879
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
7717
SMR RATING
1..100
9659
PRICE GROWTH RATING
1..100
4337
P/E GROWTH RATING
1..100
3612
SEASONALITY SCORE
1..100
5015

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCVX's Valuation (67) in the null industry is in the same range as PTGX (92) in the Biotechnology industry. This means that PCVX’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (17) in the Biotechnology industry is somewhat better than the same rating for PCVX (77) in the null industry. This means that PTGX’s stock grew somewhat faster than PCVX’s over the last 12 months.

PTGX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for PCVX (96) in the null industry. This means that PTGX’s stock grew somewhat faster than PCVX’s over the last 12 months.

PTGX's Price Growth Rating (37) in the Biotechnology industry is in the same range as PCVX (43) in the null industry. This means that PTGX’s stock grew similarly to PCVX’s over the last 12 months.

PTGX's P/E Growth Rating (12) in the Biotechnology industry is in the same range as PCVX (36) in the null industry. This means that PTGX’s stock grew similarly to PCVX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PCVXPTGX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
68%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 7 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 15 days ago
70%
Bearish Trend 7 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (PCVX: $56.69 vs. PTGX: $140.97)
Brand notoriety: PCVX and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PCVX: 125% vs. PTGX: 89%
Market capitalization -- PCVX: $8.67B vs. PTGX: $9.22B
PCVX [@Biotechnology] is valued at $8.67B. PTGX’s [@Biotechnology] market capitalization is $9.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PCVX’s FA Score shows that 0 FA rating(s) are green while PTGX’s FA Score has 2 green FA rating(s).

  • PCVX’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than PCVX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PCVX’s TA Score shows that 3 TA indicator(s) are bullish while PTGX’s TA Score has 3 bullish TA indicator(s).

  • PCVX’s TA Score: 3 bullish, 6 bearish.
  • PTGX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both PCVX and PTGX are a bad buy in the short-term.

Price Growth

PCVX (@Biotechnology) experienced а -3.95% price change this week, while PTGX (@Biotechnology) price change was -2.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.40%. For the same industry, the average monthly price growth was -11.74%, and the average quarterly price growth was +0.75%.

Reported Earning Dates

PCVX is expected to report earnings on Nov 09, 2026.

PTGX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-6.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PCVX
Daily Signal:
Gain/Loss:
PTGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
API3.X0.2837100.009438
+3.44%
API3 cryptocurrency
RAY.X1.9105890.013636
+0.72%
Raydium cryptocurrency
KLAY.X0.0337290.000128
+0.38%
Klaytn cryptocurrency
JUV.X0.316589-0.004472
-1.39%
Juventus Fan Token cryptocurrency
LSK.X0.298406-0.008026
-2.62%
Lisk cryptocurrency